OFFER DEADLINE30/10/2018 14:00 - Europe/Brussels
EU RESEARCH FRAMEWORK PROGRAMMEH2020 / Marie Skłodowska-Curie Actions COFUND
ORGANISATION/COMPANYInternational Research Projects Office
DEPARTMENTPromotion and Advisory Unit
Professor David Landeira, from the Department of Biochemistry and molecular biology II at the University of Granada, welcomes postdoctoral candidates interested in applying for an Athenea3i Research Fellowship in 2018 at this University. The information about the Fellowship conditions, how to apply, Eligibility Criteria, Selection Process, Evaluation Process, etc. is available in https://athenea3i.ugr.es/. Please note that applicants must comply with the Eligibility Criteria (https://athenea3i.ugr.es/?page_id=23).
Brief description of the institution:
The University of Granada (UGR), founded in 1531, is one of the largest and most important universities in Spain. It serves more than 60000 students per year, including many foreign students, as UGR is the leader host institution in the Erasmus program. UGR, featuring 3650 professors and more than 2000 auxiliary personnel, offers a total of 75 degrees through its 112 departments and 28 centers.
UGR is also a leading institution in research, located in the top 5/10 of Spanish universities by a variety of ranking criteria, such as national R&D projects, fellowships awarded, publications, or international funding. UGR is one of the few Spanish Universities listed in the Shanghai Top 500 ranking (http://www.arwu.org/), and it is also well recognized for its web presence (http://www.4icu.org/top200/).
Internationally, we bet decidedly by our participation in the calls of H2020, both at partner and coordination. For the duration of the Seventh Framework Programme, the UGR has obtained a total of 66 projects, with total funding of 17.97 million euros, and for H2020, until 2015, more than 25 projects with total funding of more than 6 million euros. Our more than 3,000 researchers are grouped into 365 research groups covering all scientific fields and disciplines.
Brief description of the Centre/Research Group
We are a multidisciplinary group led by Dr. David Landeira and affiliated to the Department of Biochemistry and Molecular Biology II at University of Granada. Our lab is based at the Centre for Genomics and Oncological Research (GENYO) that is co-funded by Pfizer, University of Granada and the Andalusian Regional Government. We are interested in understanding how epigenetic cell-to-cell variability impacts early mammalian development and cancer progression. We use molecular and cell biology tools combined with emerging bioinformatics platforms to study key biological systems. We use embryonic stem cells to study the role of epigenetics in the biology of pluripotent cells and human cell lines and patient samples to study the function of epigenetic factors in cancer progression. More information @ www.landeiralab.ugr.es
Cell-to-cell variability is emerging as a key regulator of essential biological processes including embryogenesis and stem cell differentiation. However, the molecular mechanisms involved are poorly characterized. Importantly, biomedical applications of cells derived from pluripotent sources is hampered by the heterogeneous nature of pluripotent cells. Thus, deeper understanding of the basis of cell heterogeneity is key to better understand stem cell biology and for the aplication of stem cells to human therapy. Because cell-to-cell variability occurs in cells with identical genomes, epigenetic modulators are anticipated to be key players in the generation of functional heterogeneity. In this study we aim to dissect the role of epigenetic modulators in cell-to-cell variability by carrying out a series of innovative experiments in a stem cell type that is clinically relevant.
Based on our unpublished work, we will dissect the impact of cell cycle and the regulation of polycomb proteins in the creation of epigenetic heterogeneity in different populations of mouse pluripotent stem cells. We will conduct genome-wide analysis of nascent RNA trascription and RNA polymerase II binding at discrete phases of the cell cycle in wild-type and polycomb-mutant pluripotent cells. Additionally, we will apply leading edge technologies to analyse changes in nucleosome positioning and gene expression at a single-cell level during cell cycle transition. The synergistic combination of genome-wide and single-cell analysis will allow us to demostrate the mechanistic link beween cell-cycle, polycomb function and nucleosomes positioning heterogenetiy in pluripotent genomes. Overall, this study will be key to unravel key modulators of epigenetic cell heterogeneity in stem cells populations.
- Life Sciences (LIFE)
For a correct evaluation of your candidature, please send the documents below to Professor David Landeira (email@example.com):
- Letter of recommendation (optional)
The responsibility for the hosting offers published on this website, including the hosting description, lies entirely with the publishing institutions. The application is handled uniquely by the employer, who is also fully responsible for the recruitment and selection processes.